Novo Nordisk A/S News - July 31, 2026

Novo Nordisk Shares Sink 10%, Ziltivekimab Fails Large Phase 3 Trial

Novo Nordisk shares fell more than 10% after its experimental drug, ziltivekimab, failed the Phase 3 ZEUS trial. The study involved over 6,300 patients with...

🔴 Novo Nordisk is trading 10.5% down today on a soft 2026 outlook and slowing obesity drug growth

Novo Nordisk is trading 10.5% down at DKK 296.25 after investors reacted negatively to a softer-than-expected 2026 outlook and slower projected growth in...